Navigation Links
Ranbaxy joins hand with Cipla to co-market ciprofloxacin

Two of the leading pharmaceutical industries, Ranbaxy Laboratories and Cipla announced an alliance to co-market Ranbaxy’s once-a-day formulation of Ciprofloxacin. The formulation had recently received Drug Controller General of India’s (DCGIs) approval for marketing in India. Ciproloxacin is a unique dosage form of the broad-spectrum antibiotic. The domestic market for ciprofloxacin is estimated to be around Rs 310 crore.

// Ciprofloxacin is the most potent fluoroquinolone with the widest spectrum bactericidal activity. It is a broad spectrum antibiotic. Hence, Ciproflxacin is being extensively used for blind therapy of infections.

According to the company, the alliance with Cipla for ciprofloxacin will be a win-win situation for both companies, enabling to leverage its combined marketing prowess and extensive distribution network. Ranbaxy official said that the company is keen that the benefits of Ciprofloxacin in terms of convenience and better patient compliance should percolate to the maximum number of doctors and patients.

The company believes that the Ciprofloxacin agreement has strengthened the spirit of cooperation that was started a few years ago between Cipla and Ranbaxy. Together, both the company brands account for over 30 per cent of the Ciprofloxacin market in India.

'"/>




Page: 1

Related medicine news :

1. Ranbaxy gets US FDA approval for Lisinopril
2. Ranbaxy Labs Entry Into Anti-Acne Market
3. Ranbaxy trying to make inroads in herbal drugs market
4. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
5. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
6. Ranbaxy opens Drug discovery centre in Gurgaon
7. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
8. SRL Ranbaxy offers quicker bird flu diagnostic test
9. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
10. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
(Date:5/15/2008)...orce, illness, violence and other problems that ca...ble to experience temporary separations from one o...indergarten. Published in the May/June issue of A...from Rochester, New York, warns that such kids are...hat these separations are good predictors of which...
(Date:5/15/2008)...y 15 /PRNewswire-FirstCall/ -- Lung cancer patient...ions may fare better as a,result, according to dat...),clinical trial. Data from the trial, which invol...for injection), will be presented at the 44th Annu...ology (ASCO) in Chicago,Ill., May 30 -- June 3, 2...
(Date:5/15/2008)...With the goal of tailoring cancer treatment for ea...y Medical Center today presented a study suggestin...ly assess treatment efficacy for patients with met...ks and sometimes months to determine if a particul... that long to observe any significant radiographic...
(Date:5/15/2008)...elecoxib, the anti-inflammatory medication also kn...afe and reduces a specific proliferation measureme...to a study from The University of Texas M. D. Ande...significance of COX-2 inhibition toward preventing...loping the disease. , The study is the first lar...
Breaking Medicine News(10 mins):Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
...nt has decided to join hands with the University o...f a new fixed dose combination or “polypills” to p...l combine four drugs- aspirin, statin(to reduce ch...ypertension. The trial will check the reliability ...
...es of water in Mars as believed earlier but ‘very ...story of ancient water on Mars," said Ken Edgett, ...ng a press conference. "Today, we are talking abou...sent on Mars right now.” The pictures taken by NA...
...re still young, and have completed their treatment... years, post-treatment, to plan a family, suggest ...ncer patients were advised to wait for two years b...ion, but novel insight has indicated, this is not ...
...transplant unit is among the first in Australia to...The first big target for embryonic stem cell resea...cher in NSW predicting major progress within four ... the Federal Parliament this week that overturns t...
Other Medicine News:Health News:A Combined Heart Pill-developed by Dr. Reddy’ 2
(Date:5/15/2008)... WOODCLIFF LAKE, N.J., May 15 /- Eisa...t results from 16 clinical data abstracts about,co...t portfolio and,preclinical oncology research have... Meeting of the American Society of Clinical Oncol... June 3, 2008., A wide variety of abstracts on Ei...
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)... MELBOURNE, Australia, May 15 /PRNewswire-FirstCal...hat the abstract for its upcoming oral,presentatio...ican Society,of Clinical Oncology (ASCO) will be a...//www.asco.org ) from 9pm on Thursday 15 May (US E...aluation of CYT997, a novel,cytotoxic and vascular...
(Date:5/15/2008)...od pressure reductions demonstrated in Blacks, His...tes and Obese Individuals, PARSIPPANY, N.J., May ... today that data presented at the American Society... Meeting (ASH 2008) in New,Orleans demonstrated th...ine and olmesartan medoxomil) safely and effective...
Breaking Medicine Technology:Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Free White Paper Available for Clinical Laboratory Managers 3A Effectively Isolating Anaerobic Bacteria 2686 1Free White Paper Available for Clinical Laboratory Managers 3A Effectively Isolating Anaerobic Bacteria 2686 2Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 1Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 2Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 3Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 4Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 5Indevus Reports Additional Positive Phase III Trial Data for NEBIDO 28R 29 1241 6Northwestern Memorial Transplant Program Initiates New Study 1237 1Northwestern Memorial Transplant Program Initiates New Study 1237 2Northwestern Memorial Transplant Program Initiates New Study 1237 3Northwestern Memorial Transplant Program Initiates New Study 1237 4February Geology and GSA Today media highlights 1985 1February Geology and GSA Today media highlights 1985 2February Geology and GSA Today media highlights 1985 3February Geology and GSA Today media highlights 1985 4February Geology and GSA Today media highlights 1985 5February Geology and GSA Today media highlights 1985 6February Geology and GSA Today media highlights 1985 7February Geology and GSA Today media highlights 1985 8February Geology and GSA Today media highlights 1985 9February Geology and GSA Today media highlights 1985 10
... PHILADELPHIA, March 15, 2007-- The cause of one ...used to treat the ongoing,threat of another childh...of Cancer Research, researchers from Stony Brook U...lent -- form of poliovirus,is effective in obliter...mice had been previously vaccinated against the vi...
... FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 15, 200...unced that the company will,present data on a nove...ence of anti-cancer activity in preclinical studie...ciation for Cancer Research,(AACR), which will tak...le Gilead,s R&D program is not currently focus...
Other Medicine Technology:Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 2Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 3Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice 4Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219,to be Presented at AACR 2Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219,to be Presented at AACR 3
Inquire
Inquire
Inquire
Bright and playful, the Thalia Girls collection is perfect for girls who love fashion and fun.Trendy shapes, colorful accents and sparkling rhinestones add flare to this exciting collection.Thalia Gi
Medicine Products: